Early Treatment With Docetaxel for Metastatic Prostate Cancer
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.
Clinical Pearls
Jyoti D. Patel, MD, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the early treatment of patients with metastatic prostate cancer.
- Treatment with docetaxel early on improves survival for men who have early evidence of metastatic prostate cancer.
- Some patients have performance status that precludes treatment. As a result, they are never treated with the most active agents.
- This analysis will change practice: It will change who cares for patients early on and how they are treated.
Related Videos
Related Content
